Thank you for your interest. Give here your contact details and you'll receive an email with the pdf file you request.
GIGA-Cardiovascular researchers identify and solve a major side effect of cancer and cholesterol treatments
In last November, Cécile Oury and her team have shown that CpG oligodeoxynucleotides (CpG ODN, small DNA molecules used in numerous cancer therapies) activate blood platelets (that greatly increases the risk of thrombotic accident) and identify potential inhibitory strategy with a drug available on the market, which completely cancels this effect and the inherent risks (J Thromb Haemost. 2017 May;15(5):983-997).
Recently, Cécile Oury and Patrizio Lancellotti, head of the cardiology department of the University Hospital of Liège and director of the GIGA-Cardiovascular Sciences Unit published a letter in “The New England Journal of Medicine” where they explain that therapeutic RNAi carrying the same phosphorothiate modification as CpG ODN molecules could increase the risk of cardiovascular events in patients.
Everyone knows that high cholesterol levels increase the risk of cardiovascular disease. Statins, inhibitors of the enzyme that controls the synthesis of cholesterol, are widely used to treat excess cholesterol and are among the best-selling drugs in the world (there are 220 million patients worldwide). Nevertheless, their efficacy and safety is currently controversial. Pharmaceutical companies have therefore started to develop new treatments with targets other than statins. Recently, one of them has developed an RNAi that inhibits the synthesis of PCSK9 protein and thus has a significant effect on the decrease of LDL cholesterol, known to be the “bad” cholesterol. This drug, still experimental today, is called inclisiran.
Cécile Oury and Patrizio Lancellotti have published this warning because this new treatment is also likely, in the same way as CpG ODN… even though the initial goal is to reduce this risk. The clinical tests carried out before the release of this drug took into account the decrease of the count platelet but the 2 researchers of the GIGA warn the pharmaceutical industry by signaling to them that that is not enough and that one must also include tests on the Platelet activation in clinical trials. It is easy to understand that this precaution is even more important in hypercholesterolemic patients in whom the cardiovascular risks are already increased tenfold. Cecile and Patrizio will be involved in a major clinical trial on inclisiran in the context of cardiovascular disease.
Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer. PDC*line Pharma is developing a new
The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –
The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder